Optimizing Surgical Site Infection Prevention in Dermatologic Surgery.

We aim to review modifiable risk factors and practices for surgical site infections (SSIs) reduction in cutaneous surgeries. The existing norms are assessed with the latest evidence, with the aim of enhancing and optimizing intra and postoperative strategies. This review seeks to offer an updated summary of the results of evidence for SSI reduction strategies tailored for practicing general dermatologists.

The Potential Uses of Omega-3 Fatty Acids in Dermatology: A Review.

Background: A growing interest exists in the relationship between diet and skin disease, with many recent studies identifying a role for omega-3 fatty acids (O3FAs) in various dermatological conditions.

Objective: Our objective was to identify the spectrum of uses for O3FA supplementation reported in literature and to evaluate the current level of evidence for its clinical application in skin disease prevention and management.

Methods: A search was conducted using Ovid MEDLINE for primary literature that examined O3FA intake and skin health.

Canadian Clinical Practice Guidelines for Rosacea.

Rosacea is a chronic facial inflammatory dermatosis characterized by background facial erythema and flushing and may be accompanied by inflammatory papules and pustules, cutaneous fibrosis and hyperplasia known as phyma, and ocular involvement. These features can have adverse impact on quality of life, and ocular involvement can lead to visual dysfunction. The past decade has witnessed increased research into pathogenic pathways involved in rosacea and the introduction of novel treatment innovations.

Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma.

Background: Basal cell carcinoma (BCC) is the most common malignancy. Growth of BCCs leads to local destruction of neighbouring healthy skin and underlying tissue and can result in significant functional and cosmetic morbidity.

Objective: To provide guidance to Canadian health care practitioners regarding management of BCCs.

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma.

Background: Squamous cell carcinoma (SCC) is the second-most common form of non-melanoma skin cancer (NMSC).

Objective: To provide guidance to Canadian health care practitioners regarding management of SCCs.

Methods: Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines).

Clinical evaluation of a cross-linked hyaluronic Acid dermal filler applied for facial augmentation.

Background: Hyaluronic Acid (HA) fillers are widely used for restoring facial volume.

Objective: A 24-week study evaluated clinical efficacy with HA.

Methods And Materials: Included were 15 healthy subjects recruited from 4 centers, between ages of 35 to 65 years, who had a Wrinkle Severity Rating Scale (WSRS) score ≥ 3, indicating moderate volume loss.

Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience.

Background: Non-melanoma skin cancer (NMSC) after kidney transplantation is common and can result in significant morbidity and mortality. Incidence and risk factors for NMSC can vary between geographic locations and there is no literature describing the incidence or risk factors for NMSC in Canada.

Methods: The purpose of this retrospective cohort study was to determine the incidence of NMSC, the time of development of NMSC, and risk factors (including sun exposure history) for NMSC in kidney transplant recipients between 1990 and 2003 in our center (n=926).

Bilateral facial apocrine chromhidrosis.

A young woman presented to the office with a history of bluish discoloration involving the superior malar region bilaterally. When the bluish discoloration became darker, she would press on her cheeks resulting in excretion of "black sweat" that temporarily lightened her skin color. Examination revealed ill-defined slightly swollen soft plaques involving both superior cheeks.

Er:YAG laser skin resurfacing.

Recent advances in Er:YAG laser technology have dramatically enhanced the ability to resurface the skin safely. Selection of precise ablation and coagulation levels allows laser surgeons to modify these variables to fit the esthetic concerns of individual patients. These systems truly represent a viable alternative to conventional CO2 laser resurfacing.